AASLD Recommendations for NASH and the Future Prospects

M3 India Newsdesk Aug 07, 2018

NASH, the chronic, but silent disease is a leading cause of liver-related morbidity and mortality worldwide, also poised to be the leading cause of liver transplants by 2020. Despite this, there are currently no FDA-approved treatment therapies for NASH. Therefore, serious concerns have been generated to develop effective treatment strategies for NASH throughout the medical community.

NASH represents the most severe form of NAFLD (non-alcoholic fatty liver disease) and...

Gastroenterology Clinical Practice International Medical Education Medicine Patient Research

Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.